Journal article icon

Journal article

ToP-DNJ, a selective inhibitor of endoplasmic reticulum α-glucosidase II exhibiting anti-flaviviral activity

Abstract:

Iminosugars have therapeutic potential against a range of diseases, due to their efficacy as glycosidase inhibitors. A major challenge in the development of iminosugar drugs lies in making a compound that is selective for the glycosidase associated with a given disease. We report the synthesis of ToP-DNJ, an antiviral iminosugar-tocopherol conjugate. Tocopherol was incorporated into the design of the iminosugar in order to direct the drug to the liver and immune cells, specific tissues of int...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1021/acschembio.7b00870

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Biochemistry
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Biochemistry
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Biochemistry
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Biochemistry
Role:
Author
Lerner–Fink Fellowship More from this funder
Unither Virology LLC More from this funder
Oxford Glycobiology Endowment More from this funder
Publisher:
American Chemical Society Publisher's website
Journal:
ACS Chemical Biology Journal website
Volume:
13
Issue:
1
Pages:
60–65
Publication date:
2017-11-21
Acceptance date:
2017-11-19
DOI:
EISSN:
1554-8937
ISSN:
1554-8929
Pmid:
29161006
Language:
English
Keywords:
Pubs id:
pubs:794740
UUID:
uuid:3d840605-2e42-412b-bd67-cba4d43cc08d
Local pid:
pubs:794740
Source identifiers:
794740
Deposit date:
2017-11-22

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP